Key Highlights
- Net income was USD 696,615 versus a USD 4.2 million loss a year earlier.
- A USD 6.0 million Warrant Liability Fair Value gain drove the swing.
- Operating expenses rose to USD 5.4 million from USD 4.3 million.
- Cash and equivalents were USD 7.6 million at September 30, 2026.
A Warrant Gain Turns the Quarter Positive
Lantern Pharma Inc. (NASDAQ:LTRN) reported third-quarter Net Income of USD 696,615 versus a net loss of USD 4,177,423 a year earlier. The swing came from a change in fair value of a warrant liability of USD 6,044,661, which more than offset a loss from operations of USD 5,377,883 versus USD 4,349,800.
Basic earnings per share were USD 0.05 versus a loss of USD 0.39, on 13,505,778 weighted average shares. Diluted net loss per share was USD 0.37 versus USD 0.39, on 13,627,375 diluted shares.
The filing's earnings per share lines show both a positive basic figure and a negative diluted figure for the same quarter, because the diluted calculation removes the warrant gain, so both are reported as presented.
Operating Costs
General and administrative expense rose to USD 3,809,301 from USD 1,912,829, while Research and Development expense fell to USD 1,568,582 from USD 2,436,971. Total operating expenses were USD 5,377,883 versus USD 4,349,800.
Interest income was USD 26,681 versus USD 100,921 and other income, net, was USD 3,156 versus USD 71,456.
Stock-based compensation was USD 777,725 for the nine months versus USD 452,061, and vesting of restricted common stock issued for services was USD 266,300 versus USD 134,100, items that the Cash Flow Statement adds back to the net loss.
Nine-Month Results and Platform
For the nine months, the net loss was USD 9,704,680 versus USD 13,045,221, with a basic loss per share of USD 0.78 versus USD 1.21 and a diluted loss per share of USD 1.08. Operating expenses were USD 12,291,220 versus USD 13,775,732, with research and development of USD 5,084,313 versus USD 8,769,305 and general and administrative expense of USD 7,206,907 versus USD 5,006,427.
The nine-month result also included a loss on issuance of warrants of USD 726,427, warrant issuance costs of USD 755,233 and a warrant fair value gain of USD 3,917,282.
The company describes itself as "an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies", with a portfolio of three clinical-stage oncology product candidates built on its RADR platform.
Deferred offering costs were USD 17,686 versus USD 88,431, and a write-off of deferred offering costs of USD 70,745 appears in the nine-month cash flow statement.
Balance Sheet and Going Concern
Cash and cash equivalents were USD 7,615,813 versus USD 4,422,838 at December 31, 2025, and marketable securities fell to USD 10,882 from USD 5,696,386. Total liabilities were USD 7,114,276, including a warrant liability of USD 1,452,428. The filing states there is substantial doubt about the company's ability to continue as a Going Concern in the absence of obtaining substantial additional funding.
Total current liabilities were USD 5,654,743 versus USD 4,501,587, and total current Assets were USD 8,413,426 versus USD 10,803,172.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...